Amy Hoover
New York University
3 Papers
Amy Hoover is an academic researcher from New York University. The author has contributed to research in topics: Placebo & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial
Francesco Montorsi,Harin Padma Nathan,Andrew McCullough,Gerald Brock,Gregory A. Broderick,Sanjeev Ahuja,Steve Whitaker,Amy Hoover,Donna Novack,Aileen Murphy,Lucio Varanese +10 more
TL;DR: Tadalafil 20 mg, taken on-demand, was an efficacious and well tolerated treatment for erectile dysfunction following BNSRRP and reported greater treatment satisfaction on the Erectile Dysfunction Inventory of Treatment Satisfaction than those receiving placebo.
213
Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.
Geert R. D'Haens,T. Kobayashi,Nathan Morris,Trevor Lissoos,Amy Hoover,X. Li,V Arora,Catherine Milch,W J Sandborn,B.E. Sands +9 more
TL;DR: In this phase 3 UC study, 300mg miri IV demonstrated statistically significant and clinically meaningful improvements vs PBO in all primary and key secondary endpoints across clinical, endoscopic, histologic, and symptomatic measures, with an acceptable safety profile.
O29 Efficacy and safety of mirikizumab in patients with ulcerative colitis: phase 3 LUCENT-1 study results
Geert R. D'Haens,Taku Kobayashi,Nathan Morris,Trevor Lissoos,Amy Hoover,Xingyuan Li,Vipin Arora,Catherine Milch,William J. Sandborn,Bruce E. Sands,Peter M. Irving +10 more
- 01 Jun 2022
TL;DR: In this article , the authors evaluated the induction efficacy and safety of miri with a Phase 3, multi-center, randomized, parallel-arm, double-blind, placebo (PBO)-controlled trial (LUCENT 1; NCT03518086) in patients with moderate-to-severe ulcerative colitis (UC) who had inadequate or loss of response, or intolerance to corticosteroids, immunosuppressants, biologic therapies, or tofacitinib.